Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Biostar Announces $9.6 Million China Acquisition

publication date: Oct 11, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Biostar Pharmaceuticals will pay 61 million RMB ($9.6 million) in cash to acquire Shaanxi Weinan Huaren Pharmaceuticals, Ltd. For Biostar, the attraction of Shaanxi Weinan is a portfolio of 86 approved drugs and one health product. Shaanxi Weinan reported revenues of $3.3 million in 2009 and $4.4 million in 2010, with net income of at least 15%. More details....

Stock Symbol: (NSDQ: BSPM)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...